Trial
NCT05130086
A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Human Immunodeficiency Virus (HIV) Infections
Intervention
Islatravir
Why stopped
Business Reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-10-17